UNSPSC 51434805: Dagapamil

This classification denotes a calcium channel blocker with the molecular formula C36H56N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64O87U613H, chemically known as 2-(3-((m-methoxyphenethyl)methylamino)propyl)-2-(3,4,5-trimethoxyphenyl)tetradecanenitrile. but generally known as dagapamil, which bears US NIH Compound Identifier 205957. European Medicines Agency schedules Dagapamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06888MIG.

UNSPSC 51434805 Dagapamil is a Commodity code that encompasses pharmaceutical products, specifically prescription medications supplied to state and local health systems, emergency services, and public health agencies. State and local governments buy medications under this code for emergency medical response, hospital formularies, and pharmacy benefit programs. The issuing bodies include city fire departments and emergency medical services, state health agencies managing pharmacy benefits, and cooperative purchasing alliances serving multiple jurisdictions. Work solicited under the code ranges from discrete medication supply contracts — such as advanced life support drugs for emergency responders — to multi-state pharmaceutical procurement initiatives that aggregate demand across state agencies and local government facilities. Vendors must comply with FDA manufacturing standards, Drug Supply Chain Security Act requirements, Good Manufacturing Practices certification, OSHA Safety Data Sheet protocols, and federal accessibility standards. Medications typically must maintain minimum shelf life guarantees and expiration dates of six months to one year or more at the time of delivery.

Recent activity appears concentrated in the South, Upper Midwest, and Southwest. The City of Tampa, Florida issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue, due April 8, 2026, with an estimated contract value of $40,000.00 and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with pricing weighted at 75 percent and availability required by May 15, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs for potential future formal procurement. Contracts typically run one to two years with optional renewal periods, and vendors are expected to maintain comprehensive insurance coverage and work through established pharmaceutical wholesalers.